121 related articles for article (PubMed ID: 30649790)
1. Increased Expression of GRP78 Correlates with Adverse Outcome in Recurrent Glioblastoma Multiforme Patients.
Wen X; Chen X; Chen X
Turk Neurosurg; 2020; 30(1):11-16. PubMed ID: 30649790
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma.
Przystal JM; Waramit S; Pranjol MZI; Yan W; Chu G; Chongchai A; Samarth G; Olaciregui NG; Tabatabai G; Carcaboso AM; Aboagye EO; Suwan K; Hajitou A
EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30808679
[TBL] [Abstract][Full Text] [Related]
3. Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Tabouret E; Tchoghandjian A; Denicolai E; Delfino C; Metellus P; Graillon T; Boucard C; Nanni I; Padovani L; Ouafik L; Figarella-Branger D; Chinot O
Oncotarget; 2015 May; 6(13):11664-75. PubMed ID: 25860928
[TBL] [Abstract][Full Text] [Related]
4. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
[TBL] [Abstract][Full Text] [Related]
6. Final Results of the Prospective Biomarker Trial PETra: [
Seidlitz A; Beuthien-Baumann B; Löck S; Jentsch C; Platzek I; Zöphel K; Linge A; Kotzerke J; Petr J; van den Hoff J; Steinbach J; Krex D; Schmitz-Schackert G; Falk M; Baumann M; Krause M
Clin Cancer Res; 2021 Mar; 27(5):1351-1360. PubMed ID: 33376095
[TBL] [Abstract][Full Text] [Related]
7. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
Gainer JL; Sheehan JP; Larner JM; Jones DR
J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.
Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Ciner F; Mertsoylu H; Tufan K
J Neurooncol; 2018 Sep; 139(2):411-419. PubMed ID: 29696530
[TBL] [Abstract][Full Text] [Related]
10. Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma.
Liu B; Liu J; Liao Y; Jin C; Zhang Z; Zhao J; Liu K; Huang H; Cao H; Cheng Q
Med Sci Monit; 2019 May; 25():3624-3635. PubMed ID: 31094363
[TBL] [Abstract][Full Text] [Related]
11. Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution.
Michaelsen SR; Christensen IJ; Grunnet K; Stockhausen MT; Broholm H; Kosteljanetz M; Poulsen HS
BMC Cancer; 2013 Sep; 13():402. PubMed ID: 24004722
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
14. Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide.
Gebhardt BJ; Dobelbower MC; Ennis WH; Bag AK; Markert JM; Fiveash JB
Radiat Oncol; 2014 Jun; 9():130. PubMed ID: 24906388
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial protein ATPase family, AAA domain containing 3A correlates with radioresistance in glioblastoma.
You WC; Chiou SH; Huang CY; Chiang SF; Yang CL; Sudhakar JN; Lin TY; Chiang IP; Shen CC; Cheng WY; Lin JC; Shieh SH; Chow KC
Neuro Oncol; 2013 Oct; 15(10):1342-52. PubMed ID: 24057885
[TBL] [Abstract][Full Text] [Related]
16. Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.
Wang J; Zuo J; Wahafu A; Wang MD; Li RC; Xie WF
CNS Neurosci Ther; 2020 Mar; 26(3):297-308. PubMed ID: 31318172
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
[TBL] [Abstract][Full Text] [Related]
18. Hyperoxia resensitizes chemoresistant glioblastoma cells to temozolomide through unfolded protein response.
Lee D; Sun S; Ho AS; Kiang KM; Zhang XQ; Xu FF; Leung GK
Anticancer Res; 2014 Jun; 34(6):2957-66. PubMed ID: 24922660
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.
Gao YT; Chen XB; Liu HL
Sci Rep; 2016 Sep; 6():32972. PubMed ID: 27595933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
